SCHEMBL3428323

SCHEMBL3428323

NS(=O)(=O)c1ccc(NN=C2CCNC(=O)c3[nH]c4ccc(F)cc4c32)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 4/20 0.67
CDK5R1 Q15078 4/20 0.67
PTGS2 P35354 4/20 0.48
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
CA9 Q16790 3/20 0.42
CA11 O75493 1/20 0.42
CDK1 P06493 1/20 0.40
CDK2 P24941 1/20 0.40
CA12 O43570 3/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
EIF2AK2 P19525 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3428321 1.00 CDK5 (0.67) CDK5CDK5R1PTGS2ALDH1A1GAA
SCHEMBL13341168 1.00 CDK5 (0.67) CDK5CDK5R1PTGS2ALDH1A1GAA
SCHEMBL13341122 0.89 CDK5 (0.55) CDK5CDK5R1PTGS2ALDH1A1CA1
SCHEMBL3426104 0.89 CDK5 (0.55) CDK5CDK5R1PTGS2ALDH1A1CA1
SCHEMBL3426106 0.89 CDK5 (0.55) CDK5CDK5R1PTGS2ALDH1A1CA1
SCHEMBL3426279 0.87 CDK5 (0.75) CDK5CDK5R1PTGS2ALDH1A1GAA
SCHEMBL3426282 0.87 CDK5 (0.75) CDK5CDK5R1PTGS2ALDH1A1GAA
SCHEMBL13341169 0.87 CDK5 (0.75) CDK5CDK5R1PTGS2ALDH1A1GAA
SCHEMBL3426443 0.80 CDK5 (1.00) CDK5CDK5R1ALDH1A1GAAL3MBTL1
SCHEMBL13341154 0.80 CDK5 (1.00) CDK5CDK5R1ALDH1A1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713958-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2010-05-11 US claimed
US-20090137555-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2009-05-28 US claimed
US-20050153955-A1 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2005-07-14 US claimed
US-7713958-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2010-05-11 US disclosed
US-20090137555-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2009-05-28 US disclosed
US-7423031-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153955-A1 Compounds and compositions as protein kinase inhibitors CDK1, CDK3, CDK11A CDK5 16/4885CDK5R1 38/4885PTGS2 3936/4885
US-20090137555-A1 Compounds and Compositions as Protein Kinase Inhibitors CDK1, CDK3, CDK2 CDK5 14/4885CDK5R1 37/4885PTGS2 3868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.